John T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson sold 10,562 shares of the firm’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $64.54, for a total transaction of $681,671.48. Following the completion of the sale, the director now directly owns 32,070 shares of the company’s stock, valued at $2,069,797.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Cytokinetics Trading Up 0.8 %

CYTK opened at $65.34 on Friday. The company has a market cap of $6.83 billion, a price-to-earnings ratio of -11.99 and a beta of 0.68. The company’s 50 day moving average is $69.91 and its 200 day moving average is $59.82. Cytokinetics, Incorporated has a 12-month low of $25.98 and a 12-month high of $110.25.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.35). The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $7.62 million. The company’s revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.45) earnings per share. As a group, analysts predict that Cytokinetics, Incorporated will post -4.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Cytokinetics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,016,889 shares of the biopharmaceutical company’s stock worth $919,800,000 after buying an additional 273,565 shares during the last quarter. First Turn Management LLC purchased a new position in Cytokinetics during the fourth quarter valued at approximately $67,414,000. Charles Schwab Investment Management Inc. lifted its holdings in Cytokinetics by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 789,969 shares of the biopharmaceutical company’s stock valued at $65,955,000 after purchasing an additional 33,257 shares in the last quarter. Norges Bank purchased a new position in Cytokinetics during the fourth quarter valued at approximately $60,299,000. Finally, Assenagon Asset Management S.A. purchased a new position in Cytokinetics during the fourth quarter valued at approximately $46,308,000.

Analysts Set New Price Targets

CYTK has been the subject of several research analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $86.00 target price on shares of Cytokinetics in a research report on Monday, April 8th. Morgan Stanley reiterated an “equal weight” rating and issued a $90.00 price target (up from $60.00) on shares of Cytokinetics in a research note on Friday, January 5th. StockNews.com lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Oppenheimer reiterated an “outperform” rating and issued a $107.00 price target on shares of Cytokinetics in a research note on Monday, March 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $108.00 price target on shares of Cytokinetics in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $79.33.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.